Sodium channel Nav1.8: Emerging links to human disease

Neurology

Volumn 86, Issue 5, 2016, Pages 473-783

  Han, Chongyang ^a   Huang, Jianying ^a   Waxman, Stephen G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHANNEL NAV1.8; SCN10A PROTEIN, HUMAN; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL DURATION; ALLODYNIA; BRAIN ELECTROPHYSIOLOGY; BRUGADA SYNDROME; CEREBELLUM; CHANNELOPATHY; FIRING RATE; GAIN OF FUNCTION MUTATION; HEART DISEASE; HEART INNERVATION; HUMAN; HYPERALGESIA; MULTIPLE SCLEROSIS; NERVE CELL EXCITABILITY; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHY; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; PURKINJE CELL; REVIEW; SMALL FIBER NEUROPATHY; SPINAL GANGLION; SUDDEN CARDIAC DEATH; ACTION POTENTIAL; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HEART DISEASES; METABOLISM; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSIOLOGY; TRENDS;

ACTION POTENTIALS; ANIMALS; DRUG DELIVERY SYSTEMS; HEART DISEASES; HUMANS; MULTIPLE SCLEROSIS; NAV1.8 VOLTAGE-GATED SODIUM CHANNEL; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; SODIUM CHANNEL BLOCKERS;

EID: 84957572837     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002333     Document Type: Review

References (49)

1. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology: XLVII: nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 2005;57:397-409.
2. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 1996;379:257-262.
3. Sangameswaran L, Delgado SG, Fish LM, et al. Structure and function of a novel voltage-gated, tetrodotoxin-resistant sodium channel specific to sensory neurons. J Biol Chem 1996;271:5953-5956.
4. Dib-Hajj SD, Ishikawa K, Cummins TR, Waxman SG. Insertion of a SNS-specific tetrapeptide in S3-S4 linker of D4 accelerates recovery from inactivation of skeletal muscle voltage-gated Na channel mu1 in HEK293 cells. FEBS Lett 1997;416:11-14.
5. Blair NT, Bean BP. Roles of tetrodotoxin (TTX)-sensitive Na+ current, TTX-resistant Na+ current, and Ca2+ current in the action potentials of nociceptive sensory neurons. J Neurosci 2002;22:10277-10290.
6. Renganathan M, Cummins TR, Waxman SG. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol 2001;86:629-640.
7. Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Acad Sci USA 2006;103:8245-8250.
8. Han C, Hoeijmakers JG, Liu S, et al. Functional profiles of SCN9A variants in dorsal root ganglion neurons and superior cervical ganglion neurons correlate with autonomic symptoms in small fibre neuropathy. Brain 2012;135:2613-2628.
9. Han C, Estacion M, Huang J, et al. Human Nav1.8: enhanced persistent and ramp currents contribute to distinct firing properties of human DRG neurons. J Neurophysiol 2015;113:3172-3185.
10. Faber CG, Lauria G, Merkies IS, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci USA 2012;109:19444-19449.
11. Han C, Vasylyev D, Macala LJ, et al. The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. J Neurol Neurosurg Psychiatry 2014;85:499-505.
12. Huang J, Yang Y, Zhao P, et al. Small-fiber neuropathy Nav1.8 mutation shifts activation to hyperpolarized potentials and increases excitability of dorsal root ganglion neurons. J Neurosci 2013;33:14087-14097.
13. Persson AK, Liu S, Faber CG, Merkies IS, Black JA, Waxman SG. Neuropathy-associated Nav1.7 variant I228M impairs integrity of dorsal root ganglion neuron axons. Ann Neurol 2013;73:140-145.
14. Estacion M, Vohra BPS, Liu S, et al. Ca2+ toxicity due to reverse Na2+-Ca2+ exchange contributes to degeneration of neurites of DRG neurons induced by a neuropathy-associated NaV1.7 mutation. J Neurophysiol 2015;114:1554-1564.
15. Andermann F, Cosgrove JB, Lloyd-Smith D, Walters AM. Paroxysmal dysarthria and ataxia in multiple sclerosis; a report of 2 unusual cases. Neurology 1959;9:211-215.
16. Espir ML, Watkins SM, Smith HV. Paroxysmal dysarthria and other transient neurological disturbances in disseminated sclerosis. J Neurol Neurosurg Psychiatry 1966;29:323-330.
17. Black JA, Dib-Hajj S, Baker D, Newcombe J, Cuzner ML, Waxman SG. Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proc Natl Acad Sci USA 2000;97:11598-11602.
18. Craner MJ, Lo AC, Black JA, et al. Annexin II/p11 is upregulated in Purkinje cells in EAE and MS. Neuroreport 2003;14:555-558.
19. Renganathan M, Gelderblom M, Black JA, et al. Expression of Nav1.8 sodium channels perturbs the firing patterns of cerebellar Purkinje cells. Brain Res 2003;959:235-242.
20. Saab CY, Gelderblom M, Black JA, Waxman SG. Abnormal Purkinje cell activity in vivo in experimental allergic encephalomyelitis. Exp Brain Res 2004;158:1-8.
21. Craner MJ, Kataoka Y, Lo AC, Black JA, Baker D, Waxman SG. Temporal course of upregulation of Na(v) 1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis. J Neuropathol Exp Neurol 2003;62:968-975.
22. Roostaei T, Sadaghiani S, Park MTM, et al. Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis. Neurology 2016;86:410-417.
23. Smith JG, Magnani JW, Palmer C, et al. Genome-wide association studies of the PR interval in African Americans. Plos Genet 2011;7:e1001304.
24. Chambers JC, Zhao J, Terracciano CM, et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet 2010;42:149-152.
25. Le Scouarnec S, Karakachoff M, Gourraud JB, et al. Testing the burden of rare variation in arrhythmia susceptibility genes provides new insights into molecular diagnosis for Brugada syndrome. Hum Mol Genet 2015;24:2757-2763.
26. Bezzina CR, Barc J, Mizusawa Y, et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013;45:1044-1049.
27. Hu D, Barajas-Martínez H, Pfeiffer R, et al. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. J Am Coll Cardiol 2014;64:66-79.
28. van den Boogaard M, Smemo S, Burnicka-Turek O, et al. A common genetic variant within SCN10A modulates cardiac SCN5A expression. J Clin Invest 2014;124:1844-1852.
29. van den Boogaard M, Elaine Wong LY, Tessadori F, et al. Genetic variation in T-box binding element functionally affects SCN5A/SCN10A enhancer. J Clin Invest 2012;122:2519-2530.
30. Qi B, Wei Y, Chen S, et al. Nav1.8 channels in ganglionated plexi modulate atrial fibrillation inducibility. Cardiovasc Res 2014;102:480-486.
31. Verkerk AO, Remme CA, Schumacher CA, et al. Functional Nav1.8 channels in intracardiac neurons: the link between SCN10A and cardiac electrophysiology. Circ Res 2012;111:333-343.
32. Yang T, Atack TC, Stroud DM, Zhang W, Hall L, Roden DM. Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res 2012;111:322-332.
33. Akopian AN, Souslova V, England S, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 1999;2:541-548.
34. Joshi SK, Mikusa JP, Hernandez G, et al. Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain 2006;123:75-82.
35. Choi JS, Waxman SG. Physiological interactions between Na(v)1.7 and Na(v)1.8 sodium channels: a computer simulation study. J Neurophysiol 2011;106:3173-3184.
36. Amir R, Michaelis M, Devor M. Membrane potential oscillations in dorsal root ganglion neurons: role in normal electrogenesis and neuropathic pain. J Neurosci 1999;19:8589-8596.
37. Kovalsky Y, Amir R, Devor M. Subthreshold oscillations facilitate neuropathic spike discharge by overcoming membrane accommodation. Exp Neurol 2008;210:194-206.
38. Liu CN, Devor M, Waxman SG, Kocsis JD. Subthreshold oscillations induced by spinal nerve injury in dissociated muscle and cutaneous afferents of mouse DRG. J Neurophysiol 2002;87:2009-2017.
39. Jarvis MF, Honore P, Shieh CC, et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA 2007;104:8520-8525.
40. Payne CE, Brown AR, Theile JW, et al. A novel selective and orally bioavailable Nav 1.8 channel blocker, PF-01247324, attenuates nociception and sensory neuron excitability. Br J Pharmacol 2015;172:2654-2670.
41. Shields SD, Cheng X, Gasser A, et al. A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. Ann Neurol 2012;71:186-194.
42. Shields SD, Butt RP, Dib-Hajj SD, Waxman SG. Oral administration of PF-01247324, a subtype-selective Nav1.8 blocker, reverses cerebellar deficits in a mouse model of multiple sclerosis. PLoS One 2015;10:e0119067.
43. Yang Y, Dib-Hajj SD, Zhang J, et al. Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Na(v)1.7 mutant channel. Nat Commun 2012;3:1186.
44. Ragsdale DS, McPhee JC, Scheuer T, et al. Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 1994;265:1724-1728.
45. Shields SD, Ahn HS, Yang Y, et al. Nav1.8 expression is not restricted to nociceptors in mouse peripheral nervous system. Pain 2012;153:2017-2030.
46. Damarjian TG, Craner MJ, Black JA, Waxman SG. Upregulation and colocalization of p75 and Nav1.8 in Purkinje neurons in experimental autoimmune encephalomyelitis. Neurosci Lett 2004;369:186-190.
47. De Simone R, Micera A, Tirassa P, Aloe L. mRNA for NGF and p75 in the central nervous system of rats affected by experimental allergic encephalomyelitis. Neuropathol Appl Neurobiol 1996;22:54-59.
48. Laudiero LB, Aloe L, Levi-Montalcini R, et al. Multiple sclerosis patients express increased levels of beta nerve growth factor in cerebrospinal fluid. Neurosci Lett 1992;147:9-12.
49. Soilu-Hanninen M, Epa R, Shipham K, et al. Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor. J Neurosci Res 2000;59:712-721.